Study | Status and age range at last follow-up | Age range at MB onset (histological type if available) | RT | Secondary malignancies | Other tumour(s) | Number of BCC |
Smith et al
8
Evans et al 19 | Alive (30 s) | Infant (desmoplastic) | Yes | BCC | Meningioma Pilocytic astrocytoma | 65 |
Smith et al
8
Evans et al 19 | Alive (30 s) | Infant (desmoplastic) | Yes | BCC | Meningioma | 3 |
Smith et al
8
Evans et al 19 | Alive (20 s) | Infant (desmoplastic) | Yes | BCC | Unilateral ovarian fibroma | 11 |
Taylor et al
14
Ng et al 23 | Alive (20 s) | NA (desmoplastic) | Yes | Meningioma | None | |
Kijima et al 26 | Alive (30 s) | Infant | NA | BCC | Meningioma | NA |
Mann et al 28 | Dead (childhood) | Infant (desmoplastic) | NA | BCC infundibulocystic | NA | |
Mann et al 28 | Dead (infant) | Infant | NA | Skin hamartoma | None | |
Guerrini-Rousseau et al 31 | Alive (10 s) | Infant (MBEN) | No | Stromal ovarian tumour | Meningioma | None |
Guerrini-Rousseau et al 31 | Dead (childhood) | Infant (MBEN) | Yes (PF only) | AML | None | |
Guerrini-Rousseau et al 31 | Alive (10 s) | Infant (MBEN) | No | Thyroid carcinoma | None | |
Guerrini-Rousseau et al 31 | Alive (30 s) | Infant (classic) | Yes (CSI) | BCC | Meningioma | >20 |
Guerrini-Rousseau et al 31 | Alive (10 s) | Infant (desmoplastic) | No | Hamartoma | None | |
Ogden et al 39 | Alive (30 s) | Infant | Yes (CSI) | Bilateral ovarian leiomyosarcoma | BCC Meningioma | >100 |
Present report | Alive (20 s) | Infant | No | Bilateral ovarian stromal tumour | None | |
Present report | Alive (childhood) | Infant (desmoplastic) | No | Ovarian fibroma | Controlateral ovarian fibroma | None |
Present report | Alive (10 s) | Infant | Yes (CSI) | Meningioma | Meningioma | None |
Present report | Alive (20 s) | Infant (MBEN) | Yes (CSI) | Meningioma | Ovarian fibrosarcoma Thyroid carcinoma | None |
Age range at last follow-up (2.2–37 years), age range at MB onset (0.5–2.5 years), age range at diagnosis of the other tumours (7–35 years)
AML, acute myeloid leukaemia; BCC, basal cell carcinoma; CSI, craniospinal radiotherapy; MB, medulloblastoma; MBEN, medulloblastoma with extensive nodularity; NA, not available; PF, posterior fossa; RT, radiotherapy.